Given full information about the risks of long-term opioid therapy, patients often see the value of exploring other options rather than thinking their physicians are reluctant to prescribe narcotics for fear of litigation or regulatory action.
AMA J Ethics. 2015;17(3):202-208. doi:
10.1001/journalofethics.2015.17.3.ecas1-1503.
Professor Wendy E. Parmet joins Ethics Talk to discuss her article, coauthored with Dr Claudia E. Haupt: “Holding Clinicians in Public Office Accountable to Professional Standards.”
Alice J. Liu joins Ethics Talk to discuss her article, coauthored with Drs David S. Im and Laura D. Hirshbein: “What Does the History of Inpatient Psychiatric Unit Design Tell Us About Balancing Safety and Healing for Patients With Suicidal Behaviors?”
The drug Neurontin is used as an example of why it is permissible for physicians to engage in off-label prescribing, but off-label marketing by pharmaceutical companies is prohibited by the FDA.